Donation provides wigs for Swedish patients with cancer

December 29, 2014 Shannon Marsh

Earlier this year,  Kerensa Corlett discovered a lump in her breast that turned out to be breast cancer.  She had no family history of breast cancer and was not due for her first mammogram until January 2015, when she turned 40.  Kerensa feels very lucky because she caught it early. She is currently undergoing chemotherapy at Swedish, but you would never know it because she is always positive and has a smile on her face. When asked, she tells her story in the hopes that she can help save a life, promoting early detection.

Kerensa is a member of the law firm Ryan Swanson & Cleveland’s Charitable Giving Committee.  With her diagnosis, the Committee asked her to identify an organization to support and she suggested the American Cancer Society. When asked why, she said, “I was scared early on at the prospect of losing my hair, and how my outward appearance might impact my confidence.  For me, self-confidence and hope are tightly bound and if in some small way I can help others find confidence and hope, then having cancer will have been worth it.  I knew immediately that I wanted to support the purchase of wigs for patients at Swedish through the American Cancer society.”

As a result of the generous $2,500 donation, the American Cancer Society was able to purchase 48 wigs for cancer patients.  These wigs will become part of the American Cancer Society wig banks located at Swedish First Hill, Edmonds, and Issaquah. American Cancer Society volunteers assist patients in need, finding just the right wig to make the side effects of treatment more manageable.  This program has impacted hundreds of women receiving their care at Swedish over the years.  Thanks to Kerensa and the donation by Ryan, Swanson & Cleveland, many more women will benefit from this program.

Previous Article
What's next after breast cancer?

The Swedish Cancer Institute offers several groups for patients and their caregivers, one of which being ...

Next Article
Gilenya fails in primary progressive multiple sclerosis trial

We recently found out that Gilenya (fingolimod), an oral treatment for relapsing multiple sclerosis (MS), d...